Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Juni 2024 10:15 ET | Quelle: COUR Pharmaceuticals

COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors

CHICAGO, June 26, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ﬁrst-in-class, disease-modifying therapies designed to induce...
21. Mai 2024 08:00 ET | Quelle: COUR Pharmaceuticals

COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

CHICAGO, May 21, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ﬁrst-in-class, disease-modifying therapies designed to induce...
30. Januar 2024 06:00 ET | Quelle: COUR Pharmaceuticals

COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical trialsParticipating investors include Roche Venture...
08. Februar 2023 08:00 ET | Quelle: COUR Pharmaceuticals

COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director

CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today...

Vorherige Seite